Artivion, Inc
Artivion, Inc. makes medical devices and implantable human tissues used in cardiac and vascular surgery, with a particular focus on aortic disease. Its core portfolio includes aortic stent grafts, On-X mechanical heart valves, surgical sealants, and preserved human tissues for implantable use. The company operates through two reportable segments, Medical Devices and Preservation Services, and sells through direct teams in North America and Europe as well as distributors in other regions. Artivion’s business is shaped by regulatory approvals, surgeon adoption, and the ability to commercialize new products and indications across global markets.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueEndovascular and hybrid stent graft systems used to treat aortic aneurysms and dissections.
Mechanical heart valves, ascending aortic prostheses, and related surgical accessories.
BioGlue and related adhesive products used to seal tissue during surgery.
Processing and preservation of cardiac and vascular implantable human tissues.
PhotoFix, PerClot, and other smaller product and distribution revenues.
Products
Reported · share of revenue- Aortic Stent Grafts36.1 %
- On X23.1 %
- Preservation Services21.6 %
- Surgical Sealants17.4 %
- Other Products1.8 %
Source: 10-K FY2025, revenue the company reports per product line (SEC XBRL). Shares are of the lines shown and add up to 100 %.
Customers
Artivion sells primarily to cardiac, vascular, thoracic, and general surgeons who use its products in complex surgical procedures. In the US and Canada, the company markets through a direct sales force to hospitals and other healthcare facilities, while in EMEA it combines direct field teams with distributors and local subsidiaries. In APAC and LATAM, the company relies more heavily on independent distributors and regional sales and clinical support specialists. Demand is driven by surgeon preference, clinical evidence, regulatory clearance, and the need for specialized products in aortic repair and valve replacement.
They buy valves, stent grafts, sealants, and tissues for complex aortic and valve procedures because product performance and clinical support directly affect outcomes.
They purchase through direct sales teams or distributors for use in operating rooms and specialty surgical programs.
They buy and resell products in APAC and LATAM where Artivion has less direct commercial infrastructure.
They rely on preserved human tissues for implantable cardiac and vascular procedures and value availability, quality, and logistics.
They use coating services and selected distributed products such as PerClot and PhotoFix for specialized surgical applications.
Strategy
Artivion’s strategy is centered on four growth areas: new products, new indications, global expansion, and business development. The company is trying to convert its aortic repair pipeline into commercial revenue by bringing acquired and internally developed products to market, including AMDS and the NEXUS family of products. It is also pursuing regulatory approvals and expanded indications, which matter because the business depends on surgeon adoption and the ability to sell in more countries and more procedures. Select acquisitions, licensing, and distribution agreements are part of the model, allowing Artivion to broaden its portfolio without building every product from scratch.
New products are the main engine for growth and help offset dependence on mature franchises.
Broader approvals increase addressable procedures and support penetration in new geographies.
Direct sales and local support improve execution in EMEA and selected emerging markets.
Acquisitions and partnerships can add products, capabilities, and distribution faster than internal development alone.
Geography
2025Artivion has a global footprint with major operating subsidiaries in the United States and Germany and additional country entities supporting sales and marketing worldwide. The company’s primary facilities are in Kennesaw, Georgia; Austin, Texas; and Hechingen, Germany, which are important for manufacturing, tissue processing, and European commercial operations. Management says revenues increased across all geographies in 2025, with the strongest growth in EMEA and North America, while aortic stent graft revenue remains mostly outside the US. The company’s commercial model is split between direct sales in North America and EMEA and distributor-led execution in APAC and LATAM, which affects pricing, regulatory execution, and working capital needs.
Share of the revenue the company reports by geography.
Risks
Artivion faces meaningful execution risk because it depends on regulatory approvals, surgeon adoption, and successful commercialization of specialized products. Its international footprint exposes it to foreign exchange volatility, compliance burdens, distributor risk, and local regulatory changes, while the company also notes the need to maintain a productive relationship with its German Works Council. The business is concentrated in On-X products and aortic stent grafts, so clinical competition, changes in treatment patterns such as TAVR, or slower uptake of new indications could affect revenue. The company also disclosed a prior cybersecurity incident that disrupted ERP, manufacturing, order processing, and shipping, highlighting operational and inventory risks in a regulated manufacturing environment.
- Cybersecurity and ERP disruptionImpact: HighLikelihood: High
A prior cyber incident temporarily disrupted operations and affected revenue, manufacturing, order processing, and shipping.
Exposure: Global operations and supply chain
- Regulatory and clinical adoption riskImpact: HighLikelihood: High
Growth depends on approvals, post-approval studies, and surgeon acceptance of new products and indications.
Exposure - Dependence on On-X product revenueImpact: HighLikelihood: Medium
A meaningful portion of revenue comes from the On-X valve franchise, so adverse clinical, regulatory, or competitive changes would have outsized impact.
Exposure: Mechanical heart valves and related products
- Supply chain and single-source dependencyImpact: HighLikelihood: Medium
Some materials, supplies, services, and products come from single or sole-source suppliers and single facilities.
Exposure: Manufacturing and tissue processing
- Foreign exchange volatilityImpact: MediumLikelihood: Medium
A large share of business is outside the US, so currency moves can distort reported growth and margins.
Exposure
Accounting
Judgemental itemsThe company sells devices, tissues, and preservation services, so timing and channel structure matter for when revenue is recorded.
Impact: Can affect quarterly comparability and segment margins
Tissue preservation and processing likely require estimates for costs to fulfill services and maintain inventory quality.
Impact: Can influence Preservation Services profitability
The disclosed incident may create unusual expenses, inventory write-offs, and insurance receivables.
Impact: Can distort operating income and cash flow in affected periods
A large international footprint means reported results are sensitive to exchange rates.
Impact: Affects reported revenue growth and operating margins
Similar listed companies
Publicly listed companies with a comparable business focus.
LeMaitre Vascular, Inc
LMAT · Surgical & Medical Instruments & Apparatus
Anteris Technologies Global Corp.
AVR · Orthopedic, Prosthetic & Surgical Appliances & Supplies
AtriCure, Inc.
ATRC · Surgical & Medical Instruments & Apparatus
AtriCure designs and sells surgical devices used by cardiac surgeons and electrophysiologists to treat atrial fibrillation, manage the left atrial appendage, and reduce post-operative pain.
Merit Medical Systems, Inc
MMSI · Surgical & Medical Instruments & Apparatus
Merit Medical Systems designs, manufactures, and markets proprietary medical devices used in interventional, diagnostic, and therapeutic procedures.
BioCardia, Inc.
BCDA · Biological Products, (No Diagnostic Substances)
ENvue Medical, Inc.
FEED · Orthopedic, Prosthetic & Surgical Appliances & Supplies
Last updated: 24/09/2026